Proton therapy takes aim at early lung cancer
NCT ID NCT07412327
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a precise type of radiation called stereotactic body proton therapy (SBPT) for people with early-stage non-small cell lung cancer who cannot have surgery or choose not to. About 65 participants will receive targeted proton beams in a few high-dose sessions. Researchers will track how long the cancer stays under control, survival rates, side effects, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Proton beam radiation (stereotactic body proton therapy)
- What this could lead to
- If successful, this could offer a precise, effective radiation option for early-stage lung cancer patients who cannot undergo surgery, potentially improving tumor control and survival.
- What could go wrong
- This is a small, single-center phase II study with only 65 participants, so results may not apply broadly. Radiation side effects to nearby organs are possible, and long-term outcomes are still being tracked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangzhou Concord Cancer Center
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection